Transasia Bio-Medicals’ international hematology range backed by European R&D is now in Tamil Nadu; to base its next hi-tech manufacturing facility in the South
Transasia Bio-Medicals Ltd., India's No. 1 In-vitro
Diagnostic (IVD) Company and among the leading global players focused on
emerging markets, today as part of its 40th anniversary celebration announced
that its international hematology range, is now available in Tamil Nadu.
- Priced 25% below comparable options, new range to make world-class diagnostics affordable for masses
Chennai, April 27,2019:
Backed by European R&D, the 3-Part Differential Analyzer(3PDA) to 5-Part
DifferentialAnalyzer (5PDA) fully automated haematology analyzers, reagents and
controls include a number of features to help institutions, clinicians and lab
technologists offer accurate diagnosis. Manufactured by ErbaLachema (100% owned
subsidiary of Transasia) in Europe, the H 360, H 560 and ELite 580
hematologyanalyzers are widely used in the European and global market.
Hematologyanalyzers are extensively used in patient and research settings to
count and characterize blood cells for disease detection and monitoring. Basic
analyzers return a complete blood count (CBC) with a three-part differential
white blood cell (WBC) count. Sophisticated analyzers measure cell morphology
and can detect small cell populations to diagnose rare blood conditions.
 |
|
(L-R)
Anil Jotwani, Senior Advisor,Transasia, MalaVazirani, Executive Director,
Transasia Bio-Medicals Ltd, Mr.Alastair Macleod, Director, UK Operations
|
The new hematology
range offers additional parameters, besides the routine oneslikePlatelet Large
Cell Ratio (PLCR) and Platelet Large Cell Concentration (PLCC),
that aid in enumeration of large or ‘giant’ platelets. The instruments thus
become very relevant for Tamil Nadu, which attracts migrant labor from rural
parts of Eastern India (West Bengal and the nearby areas), where large
platelets are prevalently seen in the blood samples, and are commonly
associated with certain blood disorders. Moreover, these parameters can be
useful in differentiating conditions such as thrombocytosis (high platelet
count) and thrombocytopenia (low platelet count), amongst others.Anemia, due to
malnutrition continues to be a pain point for the women of Tamil Nadu. Also, in
certain pockets of Salem, large number of cases of thalassemia and sickle cell
anemia are evident. Transasia’s new range can play a vital role in their
accurate diagnosis especially in remote areas.
Addressing the
media, MalaVazirani, Executive Director,
Transasia Bio-Medicals Ltd., said, “We are glad to be introducing our
hematology range, here today. Tamil Nadu holds the No. 1 spot in Indian
healthcare due to the existence of large and successful base of medical
teaching institutes in Chennai and the nearby areas. The state also has the unique
distinction of most successful implementation of Government healthcare schemes
under Public-Private Partnerships (PPP) as well as direct implementation of
programs such as National Health Mission (NHM).” “As per industry reports in
2018, India's medical devices industry is pegged at a $5.2 billion (Rs.
35,097.40 crore), most of which is imported. It is players like Transasia who
are at the forefront of changing it and driving Make in India,” she further
added.
 |
|
Anil Jotwani, Senior Advisor,Transasia, MalaVazirani, Executive Director,
Transasia Bio-Medicals Ltd, Mr.Alastair Macleod, Director, UK Operations with Management Team during Product Launch.
|
In his comments, Anil Jotwani, Senior Advisor,Transasia,
said, “The Tamil Nadu Government has always trusted Transasia for its quality
products and reliable results. Transasia has been closely associated with Tamil
Nadu Medical
Service Corporation Ltd. (TNMSC) for the successful
implementation and execution of the hematology and biochemistry testing
programs in rural areas.
Also, Transasia actively collaborated with Amma Healthcare Initiatives to make
them a grand success.”
India ranks 145th
among 176 countries on the quality and accessibility of healthcare parameter. Limited
access to quality medical infrastructure, including skilled manpower and
technologies have been the pain points of over 70% of Indians who live in
smaller towns and rural areas. Transasia has
been focusing on indigenous development & technology adoption which
facilitates affordable diagnostics through domestic manufacturing.
Talking about the newly launched range, Dr.Avi Nahar, M.D. Pathology, Business Unit Head – Hematology, Transasiasaid, “Accepted world-over for their quality, precision and ease-of-operation, the Erba range of hematology products will increase the adoption of automated hematology testing among Indian diagnostic labs.The range provides holistic solutions for clinical testing in general and targeted diagnostics which is an added advantage for pediatric and geriatric population. Other unique features include flagging of abnormal samples, RFID, large colored LCD touch screen, customizable reporting formats, ability to connect to a Laboratory Information System (LIS) for result output and ready-to-use reagents that are cyanide free and environment-friendly. By addressing many challenges that labs and pathologists face, Transasia is helping healthcare professionals (HCPs) focus on giving patients the best possible care.”
About
Transasia Bio-Medicals Ltd.:
Founded in 1979,
Transasia Bio-Medicals Ltd., India’s Leading In-vitro Diagnostic Company offers
products and solutions in Biochemistry, Hematology, Coagulation, ESR,
Immunology, Urinalysis, Critical Care, Diabetes Management, Microbiology and
Molecular Diagnostics. Transasia provides doctors and patients with reliable,
affordable and innovative Medical Diagnostic Systems, with an impressive
install base of above 65,000 equipment across India. It has a vast network of
the more than 250 service engineers, 400+ sales and marketing team, 23 zonal
offices and 350+ distributors. It is the first Indian company to manufacture
and export blood analyzers and reagents, in the 1990s.
.jpg)
.jpg)